protherics medicines development limited
protherics medicines development limited Company Information
Company Number
01939643
Website
https://www.btgplc.comRegistered Address
st. martin's court, 10 paternoster row, london, EC4M 7EJ
Industry
Other business support service activities n.e.c.
Telephone
02075750000
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
perseus bidco uk ltd 100%
protherics medicines development limited Estimated Valuation
Pomanda estimates the enterprise value of PROTHERICS MEDICINES DEVELOPMENT LIMITED at £113m based on a Turnover of £56m and 2.02x industry multiple (adjusted for size and gross margin).
protherics medicines development limited Estimated Valuation
Pomanda estimates the enterprise value of PROTHERICS MEDICINES DEVELOPMENT LIMITED at £606.8m based on an EBITDA of £38.4m and a 15.81x industry multiple (adjusted for size and gross margin).
protherics medicines development limited Estimated Valuation
Pomanda estimates the enterprise value of PROTHERICS MEDICINES DEVELOPMENT LIMITED at £248.2m based on Net Assets of £109.4m and 2.27x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Protherics Medicines Development Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Protherics Medicines Development Limited Overview
Protherics Medicines Development Limited is a live company located in london, EC4M 7EJ with a Companies House number of 01939643. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in August 1985, it's largest shareholder is perseus bidco uk ltd with a 100% stake. Protherics Medicines Development Limited is a mature, large sized company, Pomanda has estimated its turnover at £56m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Protherics Medicines Development Limited Health Check
Pomanda's financial health check has awarded Protherics Medicines Development Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 3 areas for improvement. Company Health Check FAQs
7 Strong
0 Regular
3 Weak
Size
annual sales of £56m, make it larger than the average company (£3.7m)
£56m - Protherics Medicines Development Limited
£3.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 22%, show it is growing at a faster rate (3%)
22% - Protherics Medicines Development Limited
3% - Industry AVG
Production
with a gross margin of 85.4%, this company has a lower cost of product (38.9%)
85.4% - Protherics Medicines Development Limited
38.9% - Industry AVG
Profitability
an operating margin of 68.5% make it more profitable than the average company (6.3%)
68.5% - Protherics Medicines Development Limited
6.3% - Industry AVG
Employees
with 9 employees, this is below the industry average (25)
9 - Protherics Medicines Development Limited
25 - Industry AVG
Pay Structure
on an average salary of £210.1k, the company has a higher pay structure (£50.6k)
£210.1k - Protherics Medicines Development Limited
£50.6k - Industry AVG
Efficiency
resulting in sales per employee of £6.2m, this is more efficient (£157.6k)
£6.2m - Protherics Medicines Development Limited
£157.6k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Protherics Medicines Development Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Protherics Medicines Development Limited
- - Industry AVG
Stock Days
it holds stock equivalent to 149 days, this is more than average (32 days)
149 days - Protherics Medicines Development Limited
32 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 37 weeks, this is more cash available to meet short term requirements (24 weeks)
37 weeks - Protherics Medicines Development Limited
24 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 3.6%, this is a lower level of debt than the average (63.6%)
3.6% - Protherics Medicines Development Limited
63.6% - Industry AVG
protherics medicines development limited Credit Report and Business Information
Protherics Medicines Development Limited Competitor Analysis
Perform a competitor analysis for protherics medicines development limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
protherics medicines development limited Ownership
PROTHERICS MEDICINES DEVELOPMENT LIMITED group structure
Protherics Medicines Development Limited has no subsidiary companies.
Ultimate parent company
STARK INTERNATIONAL TOPCO SA
#0134726
2 parents
PROTHERICS MEDICINES DEVELOPMENT LIMITED
01939643
protherics medicines development limited directors
Protherics Medicines Development Limited currently has 5 directors. The longest serving directors include Mr Anthony Higham (Dec 2017) and Mr Vance Brown (Feb 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Anthony Higham | England | 58 years | Dec 2017 | - | Director |
| Mr Vance Brown | United States | 54 years | Feb 2020 | - | Director |
| Jonathan Monson | United States | 50 years | Feb 2020 | - | Director |
| Jeremie Urbain | England | 46 years | Mar 2021 | - | Director |
| Mr Samuel Jenkinson | England | 47 years | Jul 2022 | - | Director |
PROTHERICS MEDICINES DEVELOPMENT LIMITED financials
Protherics Medicines Development Limited's latest turnover from December 2022 is £56 million and the company has net assets of £109.4 million. According to their latest financial statements, Protherics Medicines Development Limited has 9 employees and maintains cash reserves of £3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 56,017,000 | 37,278,000 | 36,765,000 | 30,687,000 | 32,970,000 | 26,556,000 | 22,839,000 | 21,304,000 | 20,273,000 | 16,603,000 | 14,860,000 | 6,451,000 | 4,517,000 | 4,880,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 8,172,000 | 6,112,000 | 5,657,000 | 4,341,000 | 4,034,000 | 2,471,000 | 3,218,000 | 3,930,000 | 4,859,000 | 4,172,000 | 3,116,000 | 1,645,000 | 887,000 | 793,000 |
| Gross Profit | 47,845,000 | 31,166,000 | 31,108,000 | 26,346,000 | 28,936,000 | 24,085,000 | 19,621,000 | 17,374,000 | 15,414,000 | 12,431,000 | 11,744,000 | 4,806,000 | 3,630,000 | 4,087,000 |
| Admin Expenses | 9,478,000 | 12,588,000 | 8,599,000 | 4,784,000 | 4,465,000 | 2,424,000 | 675,000 | 3,038,000 | 4,628,000 | 5,738,000 | 7,736,000 | 6,038,000 | 8,811,000 | 7,474,000 |
| Operating Profit | 38,367,000 | 18,578,000 | 22,509,000 | 21,562,000 | 24,471,000 | 21,661,000 | 18,946,000 | 14,336,000 | 10,786,000 | 6,693,000 | 4,008,000 | -1,232,000 | -5,181,000 | -3,387,000 |
| Interest Payable | 0 | 0 | 0 | 606,000 | 581,000 | 823,000 | 1,216,000 | 1,000 | 1,000 | 1,000 | 1,000 | 5,000 | 1,576,000 | 0 |
| Interest Receivable | 212,000 | 212,000 | 64,000 | 149,000 | 282,000 | 0 | 0 | 0 | 0 | 0 | 35,000 | 0 | 0 | 0 |
| Pre-Tax Profit | 38,579,000 | 18,790,000 | 22,573,000 | 21,105,000 | 24,172,000 | 20,838,000 | 17,730,000 | 14,335,000 | 10,785,000 | 6,692,000 | 4,042,000 | -1,237,000 | -6,757,000 | -3,387,000 |
| Tax | -6,852,000 | -3,483,000 | -4,286,000 | -4,009,000 | -4,732,000 | -4,069,000 | -3,397,000 | 1,332,000 | 4,780,000 | -8,000 | 1,237,000 | 501,000 | 2,016,000 | 0 |
| Profit After Tax | 31,727,000 | 15,307,000 | 18,287,000 | 17,096,000 | 19,440,000 | 16,769,000 | 14,333,000 | 15,667,000 | 15,565,000 | 6,684,000 | 5,279,000 | -736,000 | -4,741,000 | -3,387,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 31,727,000 | 15,307,000 | 18,287,000 | 17,096,000 | 19,440,000 | 16,769,000 | 14,333,000 | 15,667,000 | 15,565,000 | 6,684,000 | 5,279,000 | -736,000 | -4,741,000 | -3,387,000 |
| Employee Costs | 1,891,000 | 3,219,000 | 4,263,000 | 879,000 | 243,000 | 202,000 | 439,000 | 848,000 | 1,371,000 | 1,311,000 | 1,366,000 | 1,067,000 | 1,084,000 | 939,000 |
| Number Of Employees | 9 | 12 | 11 | 3 | 2 | 2 | 5 | 8 | 11 | 12 | 7 | 9 | 9 | 11 |
| EBITDA* | 38,367,000 | 18,578,000 | 22,509,000 | 21,562,000 | 24,471,000 | 21,661,000 | 19,007,000 | 14,554,000 | 11,005,000 | 7,129,000 | 4,444,000 | -1,088,000 | -5,135,000 | -3,335,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 304,000 | 126,000 | 138,000 | 87,000 | 956,000 | 2,718,000 | 6,115,000 | 4,780,000 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4,700,000 | 4,700,000 | 4,700,000 | 4,700,000 | 4,700,000 | 4,700,000 | 5,024,000 | 6,443,000 | 6,661,000 | 6,880,000 | 7,319,000 | 5,908,000 | 4,952,000 | 4,998,000 |
| Investments & Other | 75,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 69,000 | 63,000 | 69,000 | 87,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 4,775,000 | 4,935,000 | 4,763,000 | 4,769,000 | 4,787,000 | 5,656,000 | 7,742,000 | 12,558,000 | 11,441,000 | 6,880,000 | 7,319,000 | 5,908,000 | 4,952,000 | 4,998,000 |
| Stock & work in progress | 3,351,000 | 983,000 | 2,194,000 | 2,427,000 | 2,197,000 | 1,080,000 | 1,322,000 | 1,355,000 | 1,227,000 | 843,000 | 1,480,000 | 266,000 | 102,000 | 387,000 |
| Trade Debtors | 0 | 0 | 7,000 | 65,631,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 863,000 |
| Group Debtors | 101,900,000 | 75,303,000 | 62,560,000 | 0 | 47,505,000 | 25,128,000 | 0 | 0 | 0 | 0 | 0 | 5,688,000 | 7,163,000 | 10,143,000 |
| Misc Debtors | 588,000 | 410,000 | 368,000 | 0 | 51,000 | 13,000 | 9,000 | 66,000 | 91,000 | 88,000 | 217,000 | 258,000 | 315,000 | 709,000 |
| Cash | 2,955,000 | 2,410,000 | 6,240,000 | 786,000 | 969,000 | 5,576,000 | 863,000 | 446,000 | 761,000 | 1,740,000 | 680,000 | 537,000 | 373,000 | 914,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 108,794,000 | 79,106,000 | 71,369,000 | 68,844,000 | 50,722,000 | 31,797,000 | 2,194,000 | 1,878,000 | 2,079,000 | 2,671,000 | 2,377,000 | 6,749,000 | 7,953,000 | 13,016,000 |
| total assets | 113,569,000 | 84,041,000 | 76,132,000 | 73,613,000 | 55,509,000 | 37,453,000 | 9,936,000 | 14,436,000 | 13,520,000 | 9,551,000 | 9,696,000 | 12,657,000 | 12,905,000 | 18,014,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 425,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 729,000 |
| Group/Directors Accounts | 1,497,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,623,000 | 6,319,000 | 13,717,000 | 1,788,000 | 3,595,000 | 7,535,000 | 1,929,000 | 1,579,000 | 2,944,000 | 3,456,000 | 3,291,000 | 1,841,000 | 3,401,000 | 3,901,000 |
| total current liabilities | 4,120,000 | 6,319,000 | 13,717,000 | 2,213,000 | 3,595,000 | 7,535,000 | 1,929,000 | 1,579,000 | 2,944,000 | 3,456,000 | 3,291,000 | 1,841,000 | 3,401,000 | 4,630,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85,935,000 | 92,977,000 | 102,701,000 | 100,659,000 | 99,800,000 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 27,272,000 | 24,886,000 | 22,347,000 | 42,216,000 | 61,383,000 | 74,812,000 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 12,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 27,272,000 | 24,892,000 | 22,347,000 | 42,216,000 | 61,383,000 | 74,812,000 | 85,935,000 | 92,977,000 | 102,701,000 | 100,659,000 | 99,800,000 |
| total liabilities | 4,120,000 | 6,319,000 | 13,717,000 | 29,485,000 | 28,487,000 | 29,882,000 | 44,145,000 | 62,962,000 | 77,756,000 | 89,391,000 | 96,268,000 | 104,542,000 | 104,060,000 | 104,430,000 |
| net assets | 109,449,000 | 77,722,000 | 62,415,000 | 44,128,000 | 27,022,000 | 7,571,000 | -34,209,000 | -48,526,000 | -64,236,000 | -79,840,000 | -86,572,000 | -91,885,000 | -91,155,000 | -86,416,000 |
| total shareholders funds | 109,449,000 | 77,722,000 | 62,415,000 | 44,128,000 | 27,022,000 | 7,571,000 | -34,209,000 | -48,526,000 | -64,236,000 | -79,840,000 | -86,572,000 | -91,885,000 | -91,155,000 | -86,416,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 38,367,000 | 18,578,000 | 22,509,000 | 21,562,000 | 24,471,000 | 21,661,000 | 18,946,000 | 14,336,000 | 10,786,000 | 6,693,000 | 4,008,000 | -1,232,000 | -5,181,000 | -3,387,000 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 61,000 | 218,000 | 219,000 | 436,000 | 436,000 | 144,000 | 46,000 | 48,000 |
| Tax | -6,852,000 | -3,483,000 | -4,286,000 | -4,009,000 | -4,732,000 | -4,069,000 | -3,397,000 | 1,332,000 | 4,780,000 | -8,000 | 1,237,000 | 501,000 | 2,016,000 | 0 |
| Stock | 2,368,000 | -1,211,000 | -233,000 | 1,347,000 | 1,117,000 | -242,000 | -33,000 | 128,000 | 384,000 | -637,000 | 1,214,000 | 164,000 | -285,000 | 387,000 |
| Debtors | 26,706,000 | 12,784,000 | -2,702,000 | 40,559,000 | 22,502,000 | 25,132,000 | -57,000 | -25,000 | 3,000 | -129,000 | -5,729,000 | -1,532,000 | -4,237,000 | 11,715,000 |
| Creditors | 0 | 0 | -425,000 | 425,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -729,000 | 729,000 |
| Accruals and Deferred Income | -3,696,000 | -7,398,000 | 11,929,000 | -5,747,000 | -3,940,000 | 5,606,000 | 350,000 | -1,365,000 | -512,000 | 165,000 | 1,450,000 | -1,560,000 | -500,000 | 3,901,000 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 12,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -1,255,000 | -3,876,000 | 32,662,000 | -29,675,000 | -7,808,000 | -1,692,000 | 16,050,000 | 14,418,000 | 14,886,000 | 8,052,000 | 11,646,000 | -779,000 | 174,000 | -10,807,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 75,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 1,497,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -85,935,000 | -7,042,000 | -9,724,000 | 2,042,000 | 859,000 | 99,800,000 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | -27,272,000 | 4,925,000 | 2,539,000 | -19,869,000 | -19,167,000 | -13,429,000 | 74,812,000 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 212,000 | 212,000 | 64,000 | -457,000 | -299,000 | -823,000 | -1,216,000 | -1,000 | -1,000 | -1,000 | 34,000 | -5,000 | -1,576,000 | 0 |
| cash flow from financing | 1,709,000 | 212,000 | -27,208,000 | 23,929,000 | 2,251,000 | 4,319,000 | -20,399,000 | -13,387,000 | -11,085,000 | -6,995,000 | -9,656,000 | 2,043,000 | -715,000 | 16,771,000 |
| cash and cash equivalents | ||||||||||||||
| cash | 545,000 | -3,830,000 | 5,454,000 | -4,790,000 | -4,607,000 | 4,713,000 | 417,000 | -315,000 | -979,000 | 1,060,000 | 143,000 | 164,000 | -541,000 | 914,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 545,000 | -3,830,000 | 5,454,000 | -4,790,000 | -4,607,000 | 4,713,000 | 417,000 | -315,000 | -979,000 | 1,060,000 | 143,000 | 164,000 | -541,000 | 914,000 |
P&L
December 2022turnover
56m
+50%
operating profit
38.4m
+107%
gross margin
85.5%
+2.16%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
109.4m
+0.41%
total assets
113.6m
+0.35%
cash
3m
+0.23%
net assets
Total assets minus all liabilities
Similar Companies
protherics medicines development limited company details
company number
01939643
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
August 1985
age
39
accounts
Full Accounts
ultimate parent company
previous names
protherics molecular design limited (June 2006)
proteus molecular design limited (December 1999)
See moreincorporated
UK
address
st. martin's court, 10 paternoster row, london, EC4M 7EJ
last accounts submitted
December 2022
protherics medicines development limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 8 charges/mortgages relating to protherics medicines development limited. Currently there are 3 open charges and 5 have been satisfied in the past.
protherics medicines development limited Companies House Filings - See Documents
| date | description | view/download |
|---|
